Goodyear Tire & Rubber Co vs Medpace Holdings Inc — how do they compare? Goodyear Tire & Rubber Co trades at $6.11 (market cap $1.75B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 9.7× Goodyear Tire & Rubber Co's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| GT | MEDP | |
|---|---|---|
Market Cap | $1.75B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $10.54 | $620.59 |
52-Week Low | $5.58 | $393.42 |
Enterprise Value | $9.11B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $5.98, down 0.83% on the day, reflecting ongoing pressure from declining revenue and a significant net loss of $1.72 billion in 2025. Technical indicators are bearish, with moving averages signaling a downtrend, while fundamentals show a low P/E of 4.69 and P/B of 0.62, suggesting potential undervaluation despite negative profitability metrics like a -14.37% net income margin. Recent Q2 2026 earnings showed a loss of $0.61 per share, beating expectations but highlighting volume challenges.
GT presents a high-risk opportunity with its cheap valuation offset by weak earnings and cash flow volatility. Analyst sentiment is mixed, with 34.62% buy ratings, but risks include persistent volume declines, high debt, and competitive pressures. The stock's outlook hinges on operational improvements and market stabilization, making it speculative for value investors.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →